Form 4: Tenon Medical Director Granted 128,957 RSUs

Tenon Medical, Inc. Director Richard Ferrari was granted 128,957 restricted stock units, vesting in two tranches in 2026.

Summary

• Richard Ferrari, a Director of Tenon Medical, Inc. (TNON), was granted 128,957 Restricted Stock Units (RSUs).
• The transaction date for this grant was October 13, 2025.
• Each restricted stock unit represents a contingent right to receive one share of common stock of Tenon Medical, Inc.
• Fifty percent (50%) of the total RSUs, or 64,478.5 units, are scheduled to vest and automatically convert into common stock on January 1, 2026.
• The remaining fifty percent (50%) of the RSUs, or 64,478.5 units, are scheduled to vest and automatically convert into common stock on July 31, 2026.
• The price of the derivative security (RSU) at the time of grant was $0.

Sentiment

Score: 7

Explanation: The grant of equity to a director generally aligns their interests with shareholders, which is viewed positively for corporate governance and long-term strategy, despite the minor future dilution.

Positives

• The grant of restricted stock units to a director aligns their financial interests with the long-term performance and shareholder value of Tenon Medical, Inc.

Negatives

• The future conversion of restricted stock units into common stock will result in a minor dilution of existing shareholders' ownership.

Risks

• Future dilution of common stock upon the vesting and conversion of the 128,957 restricted stock units.
• The ultimate value of the compensation to the director is contingent on the future market price of Tenon Medical's common stock.

Future Outlook

The company anticipates the issuance of 128,957 shares of common stock in two tranches during 2026, corresponding to the vesting schedule of the granted restricted stock units.

Industry Context

The grant of restricted stock units to directors is a common and widely accepted practice across various industries for executive and director compensation, aiming to align leadership interests with long-term shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of equity compensation for directors is a standard practice observed across numerous publicly traded companies, including those in the medical device and healthcare sectors.
• While specific comparable companies or projects are not detailed in this filing, the structure of the RSU grant, including a vesting schedule, is consistent with typical compensation packages designed to incentivize long-term commitment and performance.

Related Party Transactions

• Richard Ferrari, a director of Tenon Medical, Inc., received 128,957 restricted stock units as part of his compensation package, which is a transaction between the company and a related party.

Stakeholder Impact

• Shareholders will experience minor dilution upon the vesting and conversion of the restricted stock units into common stock.
• The grant aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic focus.

Next Steps

• The first tranche of 64,478.5 restricted stock units will vest and convert into common stock on January 1, 2026.
• The second tranche of 64,478.5 restricted stock units will vest and convert into common stock on July 31, 2026.

Key Dates

Keywords

Tenon Medical, TNON, Form 4, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Richard Ferrari, Beneficial Ownership